# Hyperpolarized MR Imaging with Carbon-13 Pyruvate in the Human Body

> **NCT06645691** · PHASE2 · RECRUITING · sponsor: **National Heart Centre Singapore** · enrollment: 200 (estimated)

## Conditions studied

- Heart Failure
- Cardiometabolic Syndrome
- Cancer Diagnosis
- Cardiovascular Diseases
- Healthy Volunteers

## Interventions

- **DRUG:** Hyperpolarized 13C-pyruvate

## Key facts

- **NCT ID:** NCT06645691
- **Lead sponsor:** National Heart Centre Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-17
- **Primary completion:** 2028-05-31
- **Final completion:** 2028-05-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2024-12-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06645691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06645691, "Hyperpolarized MR Imaging with Carbon-13 Pyruvate in the Human Body". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06645691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*